Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Author Correction: Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.

Page BDG, Valerie NCK, Wright RHG, Wallner O, Isaksson R, Carter M, Rudd SG, Loseva O, Jemth AS, Almlöf I, Font-Mateu J, Llona-Minguez S, Baranczewski P, Jeppsson F, Homan E, Almqvist H, Axelsson H, Regmi S, Gustavsson AL, Lundbäck T, Scobie M, Strömberg K, Stenmark P, Beato M, Helleday T.

Nat Commun. 2019 Nov 1;10(1):5050. doi: 10.1038/s41467-019-12806-1.

2.

STAT3 differential scanning fluorimetry and differential scanning light scattering assays: Addressing a missing link in the characterization of STAT3 inhibitor interactions.

Desroses M, Busker S, Astorga-Wells J, Attarha S, Kolosenko I, Zubarev RA, Helleday T, Grandér D, Page BDG.

J Pharm Biomed Anal. 2018 Oct 25;160:80-88. doi: 10.1016/j.jpba.2018.07.018. Epub 2018 Jul 17.

3.

Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.

Page BDG, Valerie NCK, Wright RHG, Wallner O, Isaksson R, Carter M, Rudd SG, Loseva O, Jemth AS, Almlöf I, Font-Mateu J, Llona-Minguez S, Baranczewski P, Jeppsson F, Homan E, Almqvist H, Axelsson H, Regmi S, Gustavsson AL, Lundbäck T, Scobie M, Strömberg K, Stenmark P, Beato M, Helleday T.

Nat Commun. 2018 Jan 17;9(1):250. doi: 10.1038/s41467-017-02293-7. Erratum in: Nat Commun. 2019 Nov 1;10(1):5050.

4.

Identification of novel small molecules that inhibit STAT3-dependent transcription and function.

Kolosenko I, Yu Y, Busker S, Dyczynski M, Liu J, Haraldsson M, Palm Apergi C, Helleday T, Tamm KP, Page BDG, Grander D.

PLoS One. 2017 Jun 21;12(6):e0178844. doi: 10.1371/journal.pone.0178844. eCollection 2017.

5.

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Colaguori R, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW.

Leukemia. 2017 May;31(5):1253-1254. doi: 10.1038/leu.2017.14. No abstract available.

PMID:
28465516
6.

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaño JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, Uhlin M, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T.

Nat Med. 2017 Feb;23(2):256-263. doi: 10.1038/nm.4265. Epub 2017 Jan 9.

PMID:
28067901
7.

NUDT15 Hydrolyzes 6-Thio-DeoxyGTP to Mediate the Anticancer Efficacy of 6-Thioguanine.

Valerie NC, Hagenkort A, Page BD, Masuyer G, Rehling D, Carter M, Bevc L, Herr P, Homan E, Sheppard NG, Stenmark P, Jemth AS, Helleday T.

Cancer Res. 2016 Sep 15;76(18):5501-11. doi: 10.1158/0008-5472.CAN-16-0584. Epub 2016 Aug 16.

8.

STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.

Belton A, Xian L, Huso T, Koo M, Luo LZ, Turkson J, Page BD, Gunning PT, Liu G, Huso DL, Resar LM.

Leuk Lymphoma. 2016 Nov;57(11):2681-4. doi: 10.3109/10428194.2016.1153089. Epub 2016 Mar 8. No abstract available.

9.

Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.

Arpin CC, Mac S, Jiang Y, Cheng H, Grimard M, Page BD, Kamocka MM, Haftchenary S, Su H, Ball DP, Rosa DA, Lai PS, Gómez-Biagi RF, Ali AM, Rana R, Hanenberg H, Kerman K, McElyea KC, Sandusky GE, Gunning PT, Fishel ML.

Mol Cancer Ther. 2016 May;15(5):794-805. doi: 10.1158/1535-7163.MCT-15-0003. Epub 2016 Feb 12.

10.

Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2.

Carter M, Jemth AS, Hagenkort A, Page BD, Gustafsson R, Griese JJ, Gad H, Valerie NC, Desroses M, Boström J, Warpman Berglund U, Helleday T, Stenmark P.

Nat Commun. 2015 Aug 4;6:7871. doi: 10.1038/ncomms8871.

11.

3-Hydroxy-4-pyridinone derivatives designed for fluorescence studies to determine interaction with amyloid protein as well as cell permeability.

Telpoukhovskaia MA, Cawthray JF, Rodríguez-Rodríguez C, Scott LE, Page BD, Patrick BO, Orvig C.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3654-7. doi: 10.1016/j.bmcl.2015.06.059. Epub 2015 Jun 23.

PMID:
26141772
12.

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

Eiring AM, Kraft IL, Page BD, O'Hare T, Gunning PT, Deininger MW.

Leuk Suppl. 2014 Dec;3(Suppl 1):S5-6. doi: 10.1038/leusup.2014.3. Epub 2014 Dec 17. No abstract available.

13.

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW.

Leukemia. 2015 Mar;29(3):586-597. doi: 10.1038/leu.2014.245. Epub 2014 Aug 19. Erratum in: Leukemia. 2017 May;31(5):1253-1254.

14.

Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma.

Haftchenary S, Luchman HA, Jouk AO, Veloso AJ, Page BD, Cheng XR, Dawson SS, Grinshtein N, Shahani VM, Kerman K, Kaplan DR, Griffin C, Aman AM, Al-Awar R, Weiss S, Gunning PT.

ACS Med Chem Lett. 2013 Sep 8;4(11):1102-7. doi: 10.1021/ml4003138. eCollection 2013 Nov 14.

15.

Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer.

Lai AZ, Cory S, Zhao H, Gigoux M, Monast A, Guiot MC, Huang S, Tofigh A, Thompson C, Naujokas M, Marcus VA, Bertos N, Sehat B, Perera RM, Bell ES, Page BD, Gunning PT, Ferri LE, Hallett M, Park M.

Sci Signal. 2014 Apr 22;7(322):ra38. doi: 10.1126/scisignal.2004839.

PMID:
24757178
16.

Synthesis, characterization, and cytotoxicity studies of Cu(II), Zn(II), and Fe(III) complexes of N-derivatized 3-hydroxy-4-pyridiones.

Telpoukhovskaia MA, Rodríguez-Rodríguez C, Scott LE, Page BD, Patrick BO, Orvig C.

J Inorg Biochem. 2014 Mar;132:59-66. doi: 10.1016/j.jinorgbio.2013.12.003. Epub 2013 Dec 22.

PMID:
24393377
17.

3-Hydroxy-4-pyridinone derivatives as metal ion and amyloid binding agents.

Telpoukhovskaia MA, Rodríguez-Rodríguez C, Cawthray JF, Scott LE, Page BD, Alí-Torres J, Sodupe M, Bailey GA, Patrick BO, Orvig C.

Metallomics. 2014 Feb;6(2):249-62. doi: 10.1039/c3mt00135k.

PMID:
23999879
18.

Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.

Page BD, Croucher DC, Li ZH, Haftchenary S, Jimenez-Zepeda VH, Atkinson J, Spagnuolo PA, Wong YL, Colaguori R, Lewis AM, Schimmer AD, Trudel S, Gunning PT.

J Med Chem. 2013 Sep 26;56(18):7190-200. doi: 10.1021/jm3017255. Epub 2013 Sep 13.

PMID:
23968501
19.

STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy.

Camporeale A, Marino F, Papageorgiou A, Carai P, Fornero S, Fletcher S, Page BD, Gunning P, Forni M, Chiarle R, Morello M, Jensen O, Levi R, Heymans S, Poli V.

EMBO Mol Med. 2013 Apr;5(4):572-90. doi: 10.1002/emmm.201201876. Epub 2013 Mar 5.

20.

Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.

Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, Paladino D, Zhao J, Chen Y, Gunning PT, Turkson J.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9623-8. doi: 10.1073/pnas.1121606109. Epub 2012 May 23.

21.

Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.

Page BD, Khoury H, Laister RC, Fletcher S, Vellozo M, Manzoli A, Yue P, Turkson J, Minden MD, Gunning PT.

J Med Chem. 2012 Feb 9;55(3):1047-55. doi: 10.1021/jm200720n. Epub 2012 Jan 13.

PMID:
22148584
22.

An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery.

Mitra RN, Doshi M, Zhang X, Tyus JC, Bengtsson N, Fletcher S, Page BD, Turkson J, Gesquiere AJ, Gunning PT, Walter GA, Santra S.

Biomaterials. 2012 Feb;33(5):1500-8. doi: 10.1016/j.biomaterials.2011.10.068. Epub 2011 Nov 10.

23.

Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain.

Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, Turkson J, Gunning PT.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5605-9. doi: 10.1016/j.bmcl.2011.06.056. Epub 2011 Jun 30.

24.

Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules.

Fletcher S, Page BD, Zhang X, Yue P, Li ZH, Sharmeen S, Singh J, Zhao W, Schimmer AD, Trudel S, Turkson J, Gunning PT.

ChemMedChem. 2011 Aug 1;6(8):1459-70. doi: 10.1002/cmdc.201100194. Epub 2011 May 25.

25.

Signal transducer and activator of transcription 3 inhibitors: a patent review.

Page BD, Ball DP, Gunning PT.

Expert Opin Ther Pat. 2011 Jan;21(1):65-83. doi: 10.1517/13543776.2011.539205. Epub 2010 Nov 29. Review.

PMID:
21114420
26.

Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein.

Fletcher S, Drewry JA, Shahani VM, Page BD, Gunning PT.

Biochem Cell Biol. 2009 Dec;87(6):825-33. doi: 10.1139/o09-044. Review.

PMID:
19935868
27.

Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities.

Fletcher S, Singh J, Zhang X, Yue P, Page BD, Sharmeen S, Shahani VM, Zhao W, Schimmer AD, Turkson J, Gunning PT.

Chembiochem. 2009 Aug 17;10(12):1959-64. doi: 10.1002/cbic.200900172. No abstract available.

28.

Altering pyridinone N-substituents to optimise activity as potential prodrugs for Alzheimer's disease.

Scott LE, Page BD, Patrick BO, Orvig C.

Dalton Trans. 2008 Dec 7;(45):6364-7. doi: 10.1039/b815404j. Epub 2008 Oct 6.

PMID:
19002321
29.

MEX-5 asymmetry in one-cell C. elegans embryos requires PAR-4- and PAR-1-dependent phosphorylation.

Tenlen JR, Molk JN, London N, Page BD, Priess JR.

Development. 2008 Nov;135(22):3665-75. doi: 10.1242/dev.027060. Epub 2008 Oct 8.

30.
31.
32.
33.
34.
36.

ELT-1, a GATA-like transcription factor, is required for epidermal cell fates in Caenorhabditis elegans embryos.

Page BD, Zhang W, Steward K, Blumenthal T, Priess JR.

Genes Dev. 1997 Jul 1;11(13):1651-61.

37.
38.
39.

Localization of the Kar3 kinesin heavy chain-related protein requires the Cik1 interacting protein.

Page BD, Satterwhite LL, Rose MD, Snyder M.

J Cell Biol. 1994 Feb;124(4):507-19.

42.

Industrial chemical contamination of foods.

Conacher HB, Page BD, Ryan JJ.

Food Addit Contam. 1993 Jan-Feb;10(1):129-43. Review.

PMID:
8504868
43.

Survey of bottled drinking water sold in Canada. Part 2. Selected volatile organic compounds.

Page BD, Conacher HB, Salminen J, Nixon GR, Riedel G, Mori B, Gagnon J, Brousseau Y.

J AOAC Int. 1993 Jan-Feb;76(1):26-31.

PMID:
8448439
44.

Chromosome segregation in yeast.

Page BD, Snyder M.

Annu Rev Microbiol. 1993;47:231-61. Review.

PMID:
8257099
46.
47.
48.

Ethyl carbamate (urethane) in alcoholic beverages and foods: a review.

Battaglia R, Conacher HB, Page BD.

Food Addit Contam. 1990 Jul-Aug;7(4):477-96. Review.

PMID:
2203651
50.

Supplemental Content

Support Center